Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Revises Deal with Precision to Co-market miRview mets2

NEW YORK (GenomeWeb News) – Rosetta Genomics announced after the close of the market on Tuesday that it has revised its co-marketing deal with Precision Therapeutics.

Under the revised terms, reached on Oct. 11, Rosetta grants Precision co-exclusive rights to market the miRview mets2 assay in the US. Once a minimum number of tests ordered through Precision is reached in a given month, Rosetta will pay Precision a flat monthly fee, a Rosetta spokesperson said.

Rosetta will record all revenues for miRview mets2 and is responsible for sample collection, processing, and billing.

Under the original contract reached in July, Precision was paid on a per test basis by Rosetta.

The new contract also changes the terms under which Rosetta may terminate the contract by eliminating specified sales milestone. If Precision did not reach those milestones, under the original contract, Rosetta had the right to end the agreement.

The new deal took effect on Sept. 1 and has an initial term of one year and automatically renews for an additional year. Further terms were not disclosed.

The miRview mets2 assay is a microRNA-based assay for identifying the tumor of origin in cancers of unknown or uncertain primary.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.